Valentin Cebotarescu

Valentin Cebotarescu

”Nicolae Testemitanu” State University of Medicine and Pharmacy - Chișinău / Moldova
Others
AD Scientific Index ID: 4436750
-
person_outline Valentin Cebotarescu's MOST POPULAR ARTICLES
1-) Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP …M Bazinet, V Pântea, V Cebotarescu, L Cojuhari, P Jimbei, J Albrecht, ...The lancet Gastroenterology & hepatology 2 (12), 877-889, 20172492017
2-) Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos (t) ide therapyM Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ...Gastroenterology 158 (8), 2180-2194, 20201962020
3-) Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta …M Bazinet, V Pântea, V Cebotarescu, L Cojuhari, P Jimbei, M Anderson, ...Hepatology communications 5 (2), 189-202, 2021722021
4-) Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAgL Shekhtman, SJ Cotler, L Hershkovich, SL Uprichard, M Bazinet, ...Scientific Reports 10 (1), 7837, 2020372020
5-) Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in …M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ...Journal of Hepatology 66 (1), S256-S257, 2017352017